Abbott Laboratories (ABT)vsLENSAR Inc (LNSR)
ABT
Abbott Laboratories
$103.10
+1.12%
HEALTHCARE · Cap: $176.41B
LNSR
LENSAR Inc
$7.60
-5.59%
HEALTHCARE · Cap: $101.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 77202% more annual revenue ($46.59B vs $60.26M). LNSR leads profitability with a 57.6% profit margin vs 11.7%. ABT trades at a lower P/E of 33.4x. ABT earns a higher WallStSmart Score of 54/100 (C-).
ABT
Buy54
out of 100
Grade: C-
LNSR
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$74.13
Current Price
$103.09
$28.97 premium
Margin of Safety
-84.5%
Fair Value
$6.73
Current Price
$7.60
$0.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Every $100 of equity generates 36 in profit
Keeps 58 of every $100 in revenue as profit
Conservative balance sheet, low leverage
18.4% revenue growth
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : LNSR
The strongest argument for LNSR centers on Return on Equity, Profit Margin, Debt/Equity. Profitability is solid with margins at 57.6% and operating margin at 12.9%. Revenue growth of 18.4% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : LNSR
The primary concerns for LNSR are EPS Growth, Market Cap, Piotroski F-Score. A P/E of 43.4x leaves little room for execution misses.
Key Dynamics to Monitor
ABT profiles as a value stock while LNSR is a growth play — different risk/reward profiles.
LNSR carries more volatility with a beta of 0.88 — expect wider price swings.
LNSR is growing revenue faster at 18.4% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (54/100 vs 51/100) and 13.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →LENSAR Inc
HEALTHCARE · MEDICAL DEVICES · USA
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?